There is increasing evidence that targeting vascular endothelial growth factor (VEGF) in combination with immune checkpoint inhibition can enhance therapeutic efficacy [20, 21], generating a rationale for incorporation of such strategies into immunotherapy combinations in ovarian cancer. Here, VEGFA is linked to ovarian carcinoma.